Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 2:10:591-596.
doi: 10.2147/OTT.S124097. eCollection 2017.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

Josep Tabernero  1 , Volker Kunzmann  2 , Werner Scheithauer  3 , Michele Reni  4 , Jack Shiansong Li  5 , Stefano Ferrara  6 , Kamel Djazouli  7
Affiliations

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

Josep Tabernero et al. Onco Targets Ther. .

Abstract

Purpose: The global Phase III MPACT trial demonstrated superior efficacy of nab-paclitaxel plus gemcitabine over gemcitabine alone as first-line treatment for metastatic pancreatic cancer. Region was a randomization stratification factor in the MPACT trial. This subgroup analysis of MPACT examined efficacy and safety of patients treated in Western Europe.

Patients and methods: Patients received nab-paclitaxel plus gemcitabine or gemcitabine alone as first-line treatment for metastatic pancreatic cancer as previously described. A total of 76 patients were included in this analysis (n=38 for each arm).

Results: Differences between the overall Western European cohort and the intention-to-treat population included lower percentages of male patients (46% and 58%, respectively) and patients with biliary stents (8% and 17%), and higher percentages of patients with Karnofsky performance status of 90-100 (78% and 60%) and primary tumors in the body of the pancreas (48% and 31%). The median overall survival was 10.7 months with nab-paclitaxel plus gemcitabine vs 6.9 months with gemcitabine alone (hazard ratio [HR]: 0.82 [95% confidence interval (CI): 0.48-1.40]; P=0.471). Median progression-free survival was 5.3 vs 3.7 months, respectively (HR: 0.70 [95% CI: 0.37-1.33]; P=0.277). The independently assessed overall response rate was 18% vs 5% (response rate ratio, 3.50 [95% CI: 0.78-15.78]; P=0.076). The most common grade ≥3 adverse events with nab-paclitaxel plus gemcitabine and gemcitabine alone were neutropenia (46% vs 33%, respectively), leukopenia (35% vs 19%), anemia (22% vs 0%), asthenia (21% vs 6%), thrombocytopenia (14% vs 3%), and peripheral neuropathy (13% vs 3%).

Conclusion: Although a statistically significant difference between the treatment arms was not reached for efficacy endpoints, this study does report treatment benefit and a manageable safety profile associated with nab-paclitaxel plus gemcitabine in patients treated in Western Europe with metastatic pancreatic cancer.

Keywords: MPACT; Western Europe; gemcitabine; metastatic pancreatic cancer; nab-paclitaxel.

PubMed Disclaimer

Conflict of interest statement

Disclosure Josep Tabernero: consultant or advisory role, Amgen, Boehringer, BMS, Celgene, Genentech, Imclone, Lilly, Merck KGaA, Millennium, Novartis, Onyx, Pfizer, Roche, Sanofi; honoraria, Amgen, Merck KGaA, Novartis, Roche, Sanofi. Volker Kunzmann: consultant or advisory role and research funding, Celgene. Werner Scheithauer: consultant or advisory role and honoraria, Celgene. Michele Reni: consultant or advisory role, honoraria, research funding, Celgene. Jack Shiansong Li, Stefano Ferrara, Kamel Djazouli: employment, stock ownership, Celgene. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Overall survival in the Western European cohort. Abbreviations: CI, confidence interval; Gem, gemcitabine; HR, hazard ratio; mo, month; nab-P, nab-paclitaxel.
See this image and copyright information in PMC

References

    1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25(8):1650–1656. - PubMed
    1. World Health Organization GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. [Accessed November 17, 2016]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
    1. Lepage C, Capocaccia R, Hackl M, et al. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: results of EUROCARE-5. Eur J Cancer. 2015 Sep 5; Epub. - PubMed
    1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Pancreas Cancer. 2016. Available from: http://seer.cancer.gov/statfacts/html/pancreas.html.
    1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(22):2140–2141. - PubMed